LOX Inhibitor CCT365623 Small Molecule (Tool Compound)

An inhibitor of LOX. LOX and LOXL2 have important roles in promoting tumor growth in many types of cancer and LOX has been demonstrated to be a critical mediator of cancer metastasis

Contributors

Inventor	Institute
Leo Leung ; Caroline Springer	Cancer Research UK, Manchester Institute

Cat. #:	157972
Tool sub type:	Inhibitor
Research Fields:	Cell biology;Developmental biology
Purpose:	Inhibitor

Alternate name:	LOX, protein-6-lysine oxidase
Product description:	Lysyl oxidase (LOX) and its family members LOX-like (LOXL) are copper-dependent amine oxidases that covalently cross-link collagens and elastin in the tumor extracellular matrix. LOX is secreted as a catalytically inactive 50 kDa pro-protein, which is cleaved to an active 32 kDa enzyme by proteases such as procollagen C-proteinase. LOX and LOXL have variable N-termini, and share a highly conserved C-terminus, where the catalytic domain is located. The catalytic site comprises a copper binding…
Additional notes:	Patent Application Number WO 2017/141049 A1

Primary target:	Lysyl oxidase

Shipping conditions:	Dry Ice

References:	Leung et al. 2019. J Med Chem. 62(12):5863-5884. PMID: 31070916.

Unfortunately this tool is not currently available through our online checkout process. Please contact our team directly to obtain further information on accessing this tool.

Enquire about this Tool

If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Request a license

Get support

New to CancerTools?

We are a trusted, non-profit platform for cancer research products, part of Cancer Research UK – by sourcing your cancer research tools from us you help fund future cancer research.

Find out more

Related Tools for Small molecules

Cat. #

Tool Name

151833

Chk2 inhibitor CCT241533 Small Molecule (Tool Compound)

Key Info

Cat. #:	151833
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	CCT241533 blocked CHK2 activity in human tumor cell lines in response to DNA damage, as shown by inhibition of CHK2 autophosphorylation at S516, band shift mobility changes, and HDMX degradation. CCT241533 did not potentiate the cytotoxicity of a selection of genotoxic agents in several cell lines. However, this compound significantly potentiates the cytotoxicity of two structurally distinct PARP inhibitors. Clear induction of the pS516 CHK2 signal was seen with a PARP inhibitor alone, and th…

View Tool

151834

Antitumoral Quinol1h Small Molecule (Tool Compound)

Key Info

Cat. #:	151834
Sub-type:	Antitumoral
Availability:	Please enquire for quantities and pricing
Application:	Antitumor activity observed in HCT 116 (GI50 = 40 nM) and HT 29 (GI50 = 380 nM), and in breast cancer cell lines. Potent inhibitory effect in NCI 60 cells (GI50 =16 nM and LC50 = 2.24 ÂľM).

View Tool

151889

DNA-PK inhibitor NU7441 Small Molecule (Tool Compound)

Key Info

Cat. #:	151889
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	NU7441 intraperitoneally administrated at dose of 10 mg/kg maintains for at least 4 hours shows nontoxic and increases etoposide-induced tumor growth delay 2-fold in mice bearing SW620 xenografts. NU7441 increases the persistence of ÎłH2AX foci after ionizing radiationâinduced or etoposide-induced DNA damage. NU7441 (0.5 ÎźM or 1 ÎźM) appreciably increases G2-M accumulation induced by ionizing radiation, etoposide, and doxorubicin in both SW620 and LoVo cells. NU7441 causes persistence of d…

View Tool

152709

Dual DNA-PK/PI3K inhibitor KU-0060648 Small Molecule (Tool Compound)

Key Info

Cat. #:	152709
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	KU-0060648 enhances the anti-tumour activity of etoposide in both MCF7 and SW620 xenograft models, and has single-agent activity in the MCF7 xenograft model. KU-0060648 exhibits differential effects on growth inhibition, but is not profoundly cytotoxic in a panel of human cancer cell lines. It inhibits DNA-PK and PI-3K with greater potency in MCF7 than SW620 cell using cell-based assays. Five-day exposure to 1 mM KU-0060648 inhibits cell proliferation by more than 95% in MCF7 cells but only b…

View Tool

152754

CDK2 inhibitor NU6301 Small Molecule (Tool Compound)

Key Info

Cat. #:	152754
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	The prodrug NU6301 rapidly generated NU6102 in vitro in mouse plasma, and tumour NU6102 levels in vivo consistent with activity in vitro. Eight or 12 hourly dosing of 120 mg/kg NU6301 for 10 days was well tolerated in SKUT-1B tumour-bearing mice and inhibited Rb phosphorylation in tumour tissue. Two (8 hourly dosing) and 3 (12 hourly dosing) day tumour growth delay was observed (p=0.04 and p=0.007, respectively) following NU6301 administration. NU6102 selectively inhibited the growth of CDK2 WT (wild type) versus KO MEFs (knockout mouse embryo fibroblasts) (GIââ (concentration required to inhibit cell growth by 50%) 14 ÎźM versus >30 ÎźM), and was more growth-inhibitory in p53 mutant or null versus p53 WT cells (p=0.02), and in Rb (retinoblastoma protein) WT SKUT-1B versus SKUT 1 Rb deficient cells (p=0.01). In SKUT-1B cells NU6102 induced a G2 arrest, inhibition of Rb phosphorylation and cytotoxicity (LCââ 2.6 ÎźM for a 24h exposure).

View Tool

By Category

By Cancer Type

More

LOX Inhibitor CCT365623 Small Molecule (Tool Compound)

Contributors

Related Tools for Small molecules

Tool enquiry